All Articles

More targeted therapy options make their way into the updated guideline (version 1.2019) from the National Comprehensive Cancer Network (NCCN) for the management of metastatic colorectal cancer (CRC).

Updated results from the safety lead-in of the phase 3 BEACON CRC clinical trial show a mature median overall survival (OS) of 15.3 months with the triple-drug regimen of encorafenib, a BRAF inhibitor; binimetinib, a MEK inhibitor; and cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with metastatic colorectal cancer (CRC) and BRAF V600E mutation.

Sacituzumab govitecan, a novel antibody-drug conjugate directed against Trop-2, induced response in nearly 33% of patients with heavily pretreated, relapsed, or refractory metastatic urothelial cancer.

The field of oncology navigation is an integral part of a comprehensive oncology program to ensure the identification and effective removal of barriers to care, timely patient/family caregiver education, promotion of shared decision-making, patient advocacy, needed financial resources, and psychosocial support.

Oncology navigators are well positioned to help patients prepare for their future; which, with guidance, can facilitate awareness of their sensual selves.

Find out if your navigation program is limited by these barriers.

Another Approval for Keytruda

• FDA Approves Keytruda for First-Line Treatment of Non–Small-Cell Lung Cancer (TPS ≥1%)
• FDA Advises Women to Avoid Pregnancy for Only 2 Months After Final Dose of Soltamox

A focus on training nonclinical patient navigators whose role is to provide cancer information, resources, and support to remove barriers to care.